Skip to main content

Peer Review reports

From: Ethics and the marketing authorization of pharmaceuticals: what happens to ethical issues discovered post-trial and pre-marketing authorization?

Original Submission
24 Apr 2019 Submitted Original manuscript
12 Jun 2019 Author responded Author comments - Rosemarie de la Cruz Bernabe
Resubmission - Version 2
12 Jun 2019 Submitted Manuscript version 2
4 Nov 2019 Reviewed Reviewer Report
10 Jan 2020 Reviewed Reviewer Report
22 Jan 2020 Reviewed Reviewer Report
13 Apr 2020 Reviewed Reviewer Report
14 Apr 2020 Reviewed Reviewer Report
9 Jul 2020 Author responded Author comments - Rosemarie de la Cruz Bernabe
Resubmission - Version 3
9 Jul 2020 Submitted Manuscript version 3
20 Jul 2020 Reviewed Reviewer Report
22 Jul 2020 Reviewed Reviewer Report
16 Aug 2020 Reviewed Reviewer Report
3 Sep 2020 Author responded Author comments - Rosemarie de la Cruz Bernabe
Resubmission - Version 4
3 Sep 2020 Submitted Manuscript version 4
1 Oct 2020 Author responded Author comments - Rosemarie de la Cruz Bernabe
Resubmission - Version 5
1 Oct 2020 Submitted Manuscript version 5
7 Oct 2020 Author responded Author comments - Rosemarie de la Cruz Bernabe
Resubmission - Version 6
7 Oct 2020 Submitted Manuscript version 6
Publishing
13 Oct 2020 Editorially accepted
27 Oct 2020 Article published 10.1186/s12910-020-00543-w

You can find further information about peer review here.

Back to article page